
Cardiotonic Agents. 3. Synthesis and Biological Activity of Novel 6-(Substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones

Ila Sircar,* George Bobowski, James A. Bristol, Ronald E. Weishaar, and Dale B. Evans


Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105. Received June 10, 1985

Several 6-(substituted 1*H*-imidazol-4(5)-yl)-3(2*H*)-pyridazinones were synthesized and evaluated for positive inotropic activity. The 1*H*-imidazol-4-yl regioisomers 4,5-dihydro-6-(1-methyl-2-phenyl-1*H*-imidazol-4-yl)-3(2*H*)-pyridazinone (25a) and 6-(1-methyl-2-phenyl-1*H*-imidazol-4-yl)-3(2*H*)-pyridazinone (28a) were potent positive inotropic agents. By contrast, the corresponding 1*H*-imidazol-5-yl regioisomers 25b and 28b were only weak positive inotropic agents. Compounds 25a and 28a were also potent inhibitors of cardiac phosphodiesterase fraction III.


As part of an ongoing project to identify novel compounds with cardiotonic activity for the treatment of congestive heart failure (CHF), we have recently discovered and reported a new class of potent positive inotropic agents, the 4,5-dihydro-6-[4-1*H*-imidazol-1-yl)phenyl]-3-(2*H*)-pyridazinones and 6-[4-(1*H*-imidazol-1-yl)phenyl]-3-(2*H*)-pyridazinones.^{1,2} Two members of this class, 1a (CI-914) and 1b (CI-930), are presently under development for the treatment of CHF.



We have also discovered that the compound 2, in which the phenylpyridazinone moiety is attached to the 2-position of the imidazole, is also a potent positive inotropic agent.³



In order to further define the structural requirements for positive inotropic activity in this series, we synthesized some novel 3(2H)-pyridazinones having structure I in which the pyridazinone moiety is attached to the 4- or 5-position of the imidazole ring.



Some of the pyridazinones of structure I in which the pyridazinone moiety is attached to the 4-position of the imidazole ring (e.g., 25a and 28a) exhibited positive inotropic activity in the same range as 1a when tested in the anesthetized dog model.⁴ By contrast, the corresponding regioisomers 25b and 28b exhibited only weak positive inotropic activity. In this paper we report the synthesis of compounds related to structure I and discuss some of the structure-activity relationships including cardiac

- (2) Sircar, I.; Duell, B.; Bobowski, G.; Bristol, J. A.; Evans, D. B. J. Med. Chem. 1985, 28, 1405.
- (3) Sircar, I.; Bristol, J. A. DD 208615.
- (4) Evans, D. B.; Weishaar, R. E.; Kaplan, H. R. Pharmacol. Ther. 1982, 16, 303.

phosphodiesterase inhibitory activity.

Chemistry. The 6-(substituted imidazol-4(5)-yl)-3-(2H)-pyridazinones listed in Table IV were prepared from 2-aryl-1*H*-imidazole-4-methanols following the sequences shown in Scheme I. The requisite 2-phenyl-1Himidazole-4-methanols (3, 5) were obtained from the appropriate benzonitrile via the imidate hydrochloride by a modification of the literature procedure⁵ (Scheme II). The imidazolemethanol 3 was alkylated with iodomethane in presence of potassium hydroxide in N,N-dimethylformamide to give the corresponding 1-methylimidazole 4 as a single product in low to moderate yield. Manganese dioxide oxidation of 4 gave an aldehyde that was found to be identical with 9a. In practice, it was found advantageous to oxidize 3 to the aldehyde 8 which was then alkylated with (i) dimethyl sulfate under phase-transfer conditions and (ii) iodomethane in the presence of potassium hydroxide to give a 3:2 mixture of 4- and 5-formyl derivatives (9a and 9b), respectively, in 70% combined vield. The isomers were separated by column chromatography over silica gel and characterized. The ¹H NMR spectrum (CDCl₃) of **9a** (4-formyl) shows an N-methyl resonance at δ 3.75, an imidazole proton at δ 7.64, and the formyl proton (CHO) at δ 9.80. By contrast, the N-methyl group of **9b** (5-formyl) resonates at δ 3.95 and the formyl proton at δ 9.65. Thus the N-CH₃ of **9b** is deshielded by the anisotropic effect of the 5-formyl functionality relative to 9a. Nuclear Overhauser studies (conducted at 360 MHZ in degassed Me_2SO-d_6 solution) further confirm the assignment of structures 9a and 9b, respectively. Irradiation of the N-methyl signal at δ 3.83 in **9a** caused a significant increase in the intensity of the imidazole singlet at δ 8.18, with no effect on the aldehyde singlet at δ 9.75. Conversely, irradiation of the N-methyl signal at δ 3.93 in **9b** had no effect on the singlet at δ 8.00 but caused a significant increse in the intensity of the aldehyde singlet at δ 9.76.


Since the separation of isomers 9a and 9b was inconvenient, the mixture was used for further transformations. Reaction of the mixture of 9a and 9b with morpholine and KCN in the presence of *p*-toluenesulfonic acid gave the morpholineacetonitrile derivatives 13a and 13b, which underwent Michael addition to 2-propenenitrile⁶ in the presence of base to afford 16a and 16b, respectively. Use of methyl acrylate instead of 2-propenenitrile failed to give the esters corresponding to 16a and 16b. Attempted addition of 2-butenenitrile to 13 to obtain the methyl homologue of 16 was also unsuccessful. Treatment of 16a and 16b with aqueous acetic acid at 100 °C gave a mixture of crystalline γ -oxo nitrile derivatives 19a and 19b. Hydrolysis of 19a and 19b with 6 N HCl gave a mixture of

Bristol, J. A.; Sircar, I.; Moos, W. H.; Evans, D. B.; Weishaar, R. E. J. Med. Chem. 1984, 27, 1099.


⁽⁵⁾ Dziuron, P.; Schunack, W. Arch. Pharm. (Weinheim, Ger.) 1973, 306, 349.

⁽⁶⁾ Albright, J. B.; McEvoy, F. J.; Moran, B. J. Heterocycl. Chem. 1978, 15, 881.

Scheme I



Scheme II



 γ -oxo acids 22a and 22b. This upon treatment with hydrazine in refluxing ethanol resulted in a mixture of 4,5dihydropyridazinones 25a and 25b, which was separated by fractional crystallization. Manganese dioxide oxidation of pure isomers 25a and 25b gave pyridazinone derivatives 28a and 28b, respectively.

The reaction of 3 with benzyl bromide gave a single isomer which was assigned the structure 7 based on the analogy discussed earlier. Compound 7 was oxidized by MnO_2 to give an aldehyde 12. Following the previous reaction sequences, 12 was subsequently converted to the 4,5-dihydropyridazinone 27a, which was oxidized to the pyridazinone 30a.

The dimethoxy analogue 5 was converted to the corresponding aldehyde 10a, which on alkylation with iodomethane gave a 3:2 mixture of 11a and 11b. These were easily separated by fractional crystallization. Compound 11a was converted to the 4,5-dihydropyridazinone 26a and the pyridazinone 29a by following the same reaction sequence as discussed earlier. Compound 11b formed the corresponding morpholineacetonitrile derivative, which failed to undergo Michael addition to 2-propenenitrile.


Biological Results

The pyridazinones in Tables III and IV were evaluated intravenously in an acutely instrumented anesthetized dog model for positive inotropic activity as described briefly in the Experimental Section.⁴ Heart rate, myocardial contractility (derived by measuring dP/dt_{max} of left ventricular pressure), and aortic blood pressure were recorded. Dose-response curves were determined with at least four doses of each compound.

Compound 25a and its oxidized product 28a produced dose-related increases in dP/dt_{max} comparable to 1a when tested in anesthetized dogs (Table V). These effects were associated with small increases in heart rate and small decreases in blood pressure. The decreases in mean arterial blood pressure seen with these agents (25a and 28a) at their inotropic ED₅₀ were of the same magnitude as seen with 1a. The corresponding regioisomers 25b and 28b were significantly less potent. Changing the N-alkyl substitution from methyl to benzyl, 27a and 30a, resulted in significant loss of activity. Compounds 26a and 29a in which the phenyl group is substituted with 3,4-dimethoxy groups were also inactive.

Since selective inhibition of a specific molecular form (type III) of cardiac phosphodiesterase (PDE) represents the principal component of the positive inotropic action of 1 (a and b),¹ both isomers 25a and 25b as well as their analogues were evaluated for their inhibitory effects of cardiac PDE III and the results are shown in Table VI. These data provide an explanation for the significantly different relative cardiotonic potencies of two isomes 25a and 25b. Both 25a and 28a, the 4-yl regioisomers, were potent inhibitors of cardiac PDE III (IC₅₀ = 12.1 and 5.0


Table I. 2-Aryl-4-1H-imidazole-4-methanols



						R		
compd	R	R′	formula	yield, %	mp, °C	crystn solvent	UV, λ_{max} (ϵ)	¹ H NMR, δ
4	CH ₃	Н	$C_{11}H_{12}N_2O$	45	129-130	Et ₂ O/EtOAc	260 (11 085)	3.65 (s, 3 H, NCH ₃), 4.20 (br, 1 H, OH), 4.60 (s, 2 H, CH ₂ OH), 6.85 (s, 1 H, H-5), 7.22–7.65 (m, 5 H, aromatic) ^a
5	н	OCH3	$C_{12}H_{14}N_2O_3$	76	177–178	CH₃CN	278 (18060)	3.73 [s, 3 H, $(3'-OCH_3)$], 3.77 [s, 3 H, 4'- (OCH_3)], 4.38 (s, 2 H, CH_2OH), 4.90 (s, 1 H, CH_2OH), 6.90–7.05 (m, 2 H, H-5 and H-5'), 7.38–7.60 (m, 2 H, H-2' and H-6'), 12.20 (1 H, NH)
6	CH3	OCH3	$C_{13}H_{16}N_2O_3$	44	162–163	EtOAc	264 (13630)	3.67 (s, 3 H, NCH ₃), 3.80 [s, 6 H, Ar $(OCH_3)_2$], 4.35 (d, $J = 5.5$ Hz, 2 H, CH ₂ OH), 4.83 (t, $J = 5.5$ Hz, 1 H, OH), 6.95–7.20 (m, 4 H, H-5 and 3 H, aromatic)
7	$CH_2C_6H_5$	Н	C ₁₇ H ₁₆ N ₂ O	60	178–179	EtOAc	258 (9030)	4.40 (d, $J = 6.0$ Hz, 2 H, CH ₂ OH), 4.86 (t, $J = 6.0$ Hz, 1 H, OH), 5.28 (s, 2 H, NCH ₂), 6.95–7.60 (m, 10 H, aromatic)

^a¹H NMR spectra were recorded in CDCl₃.

 Table II.
 2-Aryl-1H-imidazole-4(or 5)-carboxaldehydes




	_	_	_			crystn	UV,	IR (cm ⁻¹),	· · · · · · · · · · · · · · · · · ·
compd	R	R ₁	R_2	formula	mp, °C	solvent	$\lambda_{\max}(\epsilon)$	ν _{C==0}	¹ H NMR, δ
8	н	н	4-CH0	C ₁₀ H ₈ N ₂ O		CH3CN/THF	286 (19180)	1660	 7.30–7.55 (m, 3 H, H-5 and 2 H, aromatic), 7.95–8.10 (m, 3 H, aromatic), 9.70 (s, 1 H, CHO), 13.30 (NH)
9a	СН₃	н			109–110	EtOAc/cyclohexane	266 (15130)	1690	 3.75 (s, 3 H, NCH₃), 7.35–7.60 (m, 5 H, aromatic), 7.64 (s, 1 H, H-5), 9.82 (s, 1 H, CHO)^a 3.82 (s, 3 H, NCH₃), 7.52 (m, 3 H, aromatic), 7.75 (m, 2 H, aromatic), 8.18 (s, 1 H, H-5), 9.75 (s, 1 H, CHO)
9b	CH3	н	5-CHO	C ₁₁ H ₁₀ N ₂ O	94–95	[(CH ₃) ₂ CHO] ₂ O	265 (15110)	1692	 3.95 (s, 3 H, NCH₃), 7.35–7.70 (m, 5 H, aromatic), 7.80 (s, 1 H, H-4), 9.68 (s, 1 H, CHO)^a 3.93 (s, 3 H, NCH₃), 7.63 (m, 3 H, aromatic), 7.74 (m, 2 H, aromatic), 8.00 (s, 1 H, H-4), 9.76 (s, 1 H, CHO)
10 a	н	OCH3	4-CHO	$C_{12}H_{12}N_2O_3$	203–204	THF	307 (18020), 253 (10635)	1660	3.78 [s, 6 H, $(OCH_3)_2$], 6.98 (d, $J = 8.0$ Hz, 1 H, H-5'), 7.68 (m, 2 H, H-2' and H-6'), 7.95 (s, 1 H, H-5'), 9.63 (S, 1 H, CHO), 13.20 (NH)
11a	CH3	OCH3	4-CHO	$C_{13}H_{14}N_2O_3$	137–138	(CH ₃) ₂ CHOH	262 (15600)	1678	3.76 [s, 9 H, (CH ₃) ₃], 6.92–7.28 (m, 3 H, aromatic), 8.03 (s, 1 H, H-5), 9.64 (s, 1 H, CHO)
11 b	CH3					EtOAc/cyclohexane	262 (15650)	1668	3.83 [s, 6 H, (OCH ₃) ₂], 3.92 (s, 3 H, NCH ₃), 6.82-7.22 (m, 3 H, aromatic), 7.75 (s, 1 H, H-4), 9.66 (s, 1 H, CHO) ^a
1 2a	$CH_2C_6H_5$	н	4-CHO	C ₁₇ H ₁₄ N ₂ O	97–98	(CH ₃) ₂ CHOH/CH ₃ CN	263 (15030)	1685, 16 53	5.23 (s, 2 H, ArNCH ₂), 6.95–7.55 (m, 10 H, aromatic), 7.60 (s, 1 H, H-5), 9.88 (s, 1 H, CHO) ^a

^a¹H NMR spectra were recorded in CDCl₃.

						R1-	3 N 2 N N R	R7		
		_	_				crystn	UV,	IR (cm^{-1})	•
compd	R	R ₁	R ₇	formula	yield, %	mp, ^b °C	solvent	$\lambda_{\max}(\epsilon)$	$\nu_{\rm C}=0$	¹ Η NMR, δ
25a	CH3	н	4	C ₁₄ H ₁₄ N ₄ O	30	271-272	C ₂ H ₅ OH	303 (26 000)	1672	2.40 (t, $J = 7.0$ Hz, CH_2 -5'), 2.88 (t, $J = 7.0$ Hz, CH_2 -4'), 3.80 (s, NCH ₃), 10.80 (s, NH)
25b	CH3	Н	5	$C_{14}H_{14}N_4O$	23	214-215	EtOAc	290 (22 000)	1675	2.40 (t, $J = 7.0$ Hz, CH_2 -5'), 2.95 (t, $J = 7.0$ Hz, CH_2 -4'), 3.77 (s, NCH ₃), 10.78 (s, NH)
26a	CH3	OCH3	4	$C_{16}H_{18}N_4O_3$	81	180–182	C ₂ H ₅ OH	238 (11100), 298 (24000)	1668	2.32 (t, $J = 7.5$ Hz, CH_2-5'), 2.88 (t, $J = 7.5$ Hz, CH_2-4'), 3.75 (s, NCH_3), 3.82 [s, 6 H, $(OCH_3)_2$], 10.75 (NH)
27a	$CH_2C_6H_5$	Н	4	C ₂₀ H ₁₈ N ₄ O·HCl	60	241-242	C ₂ H ₅ OH	292 (21 800)	1680	2.50 (t, $J = 8.0$ Hz, CH_2 -5'), 3.00 (t, $J = 8.0$ Hz, CH_2 -4'), 5.45 (s, 2 H, NCH ₂), 8.35 (s, 1 H, H-5), 11.15 (s, 1 H, NH ⁺)

^aCombined yield of 25a and 25b is 53%. ^b Melts with decomposition.

Table IV. 6-(1-Alkyl-2-aryl-1H-imidazol-4(or 5)-yl)-3(2H)-pyridazinones



^a Melts with decomposition.

Table V. Cardiovascular Profile of Pyridazinones inAnesthetized Dogs

	- 8-		% change	<u> </u>
	dose,			blood
compd (n) ^a	mg/kg	$\mathrm{d}P/\mathrm{d}t_{\mathrm{max}}$	heart rate	pressure
$1a^{b}$ (6)		/		
Iu (0)	0.01	10.2 ± 1.3	0 ± 1.2	-0.7 ± 0.4
	0.03	37.2 ± 8.0	5.6 ± 3.4	-4.1 ± 1.0
	0.10	74.2 ± 13.3	6.2 ± 5.8	-5.3 ± 1.6
	0.31	127.3 ± 25.0		-13.2 ± 2.8
	1.0	146.7 ± 25.0	33.8 ± 17.0	-22.4 ± 2.8
2 (2)	0.01	95.0	15	1.0
	0.01 0.03	$35.0 \\ 82.5$	$1.5 \\ 12.5$	-1.0 -2.5
	0.03	119.5	31.5	-26.0
	0.31	111.5	30.5	-26.5
25a (2)	0.01	111.0	0010	20.0
	0.01	16.0	3.5	-1.2
	0.03	54.0	13.0	-5.0
	0.10	89.5	29.5	-11.8
	0.31	115.0	34.0	-23.2
	1.0	95.0	29.5	-31.8
25b (2)	0.0.	-	• •	
	0.01	7.0	3.0	1.75
	0.03	10.0	3.5 4.5	1.75
	0.10 0.31	11.0 16.5	4.5 5.0	1.50 0.0
	1.0	30.5	5.5	-2.25
26a (2)	1.0	00.0	0.0	2.20
	0.01	2	2.5	-1.0
	0.03	2.5	0.5	-1.25
	0.1	2.0	1.5	-0.25
	0.31	9.5	5.0	0
	1.0	0	8.5	1.5
27a (2)				
	0.01	2.5	2.0	1.0
	0.03	4.5	1.5	-0.5
	0.10 0.31	$12.5 \\ 10.5$	19.0 18.5	0 -4.5
	1.0	3.0	8.0	-4.75
28a (2)	1.0	0.0	0.0	4.10
(-)	0.01	8.0	1.5	-1.5
	0.03	25.5	9.5	-0.25
	0.1	68.0	21.5	-6.5
	0.31	150.0	50.5	-15.75
661 (6)	1.0	186.0	63.5	-31.25
28b (2)	0.01	0.0	05	1 5
	0.01 0.03	2.0 5.0	-0.5 -1.0	$1.5 \\ 0.75$
	0.05	8.0	-1.5	-1.75
	0.31	14.0	-3.0	-0.25
	1.0	17.0	-1.5	-2.5
29a (2)				
	0.01	3.5	1.5	0
	0.03	6.0	1.0	1.5
	0.1	4.5	-0.5	0
	0.31	5.0	-1.0	-1.0
20 a (2)	1.0	13.0	0.5	-4.5
30a (2)	0.1	21.0	3.0	8.5
	0.03	21.0 29.0	-1.0	6.5 6.5
	0.10	17.0	-1.0	8.0
	0.31	28.0	3.0	3.0
	1.0	55.0	8.0	2.0

^a Values shown are the arithmetic mean of two separate experiments except for compound 1a: n is the number of dogs. ^b Significant p < 0.05 compared to control.

 μ M, respectively). By contrast, compounds **25b** and **28b**, the 5-yl regioisomers, demonstrated only weak inhibitory effects.

In summary, structure-activity relationships of $6 \cdot (1H-imidazol-4(5)-yl)$ pyridazinones showed the potent positive inotropic activity resides in one regioisomer only, namely **25a** and **28a**, respectively. These compounds were not studied in depth because of their poor oral activity in conscious chronically instrumented dogs.

Table VI. IC₅₀ Values on Type III of Guinea Pig Phosphodiesterase for 4,5-Dihydro-3(2H)-pyridazinones and 3(2H)-Pyridazinones

compd	IC_{50} , ^{<i>a</i>} $\mu \mathrm{M}$	compd	IC_{50} , ^{<i>a</i>} μM
25a	12.1	26a	128.0
25b	38.0	29a	75.0
28a	8.0	1 a	6.1
28b	160.0		

 o IC₅₀ values were determined by measuring the inhibiting effects of each agent over a concentration range of 1.0×10^{-7} to 1.0×10^{-4} M or 1.0×10^{-6} to 1.0×10^{-3} M for the less potent agents. Each value represents the mean of two to four experiments using different preparations of phosphodiesterases and were calculated from the dose–response curve.

Experimental Section

Melting points were determined on a Thomas-Hoover capillary melting point apparatus and are uncorrected. ¹H NMR spectra were recorded (Me₂SO- d_6 unless otherwise stated) on a Varian EM 390 and XL 200 spectrometer with Me₄Si as an internal standard. IR spectra were recorded on a Nicolet FT-IRMS-1 or FT-IR2 OSX spectrophotometer. Mass spectra were obtained on a Finnigan 1015 Quadrupole mass spectrometer. UV spectra were recorded in CH₃OH on a Cary 118 UV-visible recording spectrophotometer. TLC were performed on silica gel G (Stahl), and the plates were visualized with UV light and/or I₂ vapor. The elemental analyses (C, H, and N) for all new compounds were within ±0.4% of theory.

2-(3,4-Dimethoxyphenyl)-1*H*-imidazole-4-methanol (5, Table I). HCl gas was bubbled for 30 min into a cooled solution of 50.0 g (0.307 mol) of 3,4-dimethoxybenzonitrile in 550 mL of anhydrous methanol and the solution allowed to stand overnight at 23 °C. The resulting white crystals of methyl 3,4-dimethoxybenzenecarboximidate hydrochloride (24.9 g) were collected, mp 163-164 °C. On addition of 300 mL of ether to the mother liquor, a second crop of 18.3 g (total yield: 61%) was obtained, mp 163-164 °C; ¹H NMR (Me₂SO-d₆) δ 3.03 [s, 3 H, Ar C-(NH)OCH₃], 3.78 [s, 6 H, Ar (OCH₃)₂]. Anal. (C₁₀H₁₃NO₃·HCl) C, H, N.

A solution of 24.7 g (0.106 mol) of the above imidate and 9.31 g (0.11 mol) of 1,3-dihydroxyacetone in 90 g of anhydrous ammonia was heated at 68 °C for 4 h at 420 psi. After cooling, excess ammonia was removed, the solution was poured into 1 L of cold water, and the resulting solid was filtered to give 18.1 g (76%) of 5, mp 176–177 °C dec. Crystallization from acetonitrile gave 5 as white crystals, mp 177–178 °C dec.

General Procedure for Alkylation of 2-Aryl-1*H*imidazole-4-methanols (Table I). 1-Methyl-2-phenyl-1*H*imidazole-4-methanol (4). To a stirred solution of 7.0 g (0.04 mol) of 2-phenyl-1*H*-imidazole-4-methanol (3)³ and 11.2 g (0.2 mol) of finely powdered potassium hydroxide in 100 mL of anhydrous *N*,*N*-dimethylformamide was added 6.2 g (0.044 mol) of iodomethane and the mixture was heated at 55 °C for 5 h. The TLC (chloroform-methanol, 4:1) showed the absence of starting material (R_f 0.25), the new product appearing as a single spot of R_f 0.45. The solution was evaporated in vacuo, and the residue was dissolved in cold water and extracted twice with 250 mL of ethyl acetate. The combined extracts were washed, dried over Na₂SO₄, and evaporated. Chromatographic purification of the crude residue over 100 g of silica gel (using EtOAc-ether (1:1) as the eluent) afforded 3.4 g of pure single isomer 4.

By use of an identical procedure, the dimethoxy analogue 5 was converted to the corresponding 1-methyl derivative 6. The 1-(phenylmethyl) homologue 7 was also obtained from 5 and benzyl bromide by the above procedure.

General Procedure for Öxidation of 1H-Imidazole-4methanols (3-7, Table II). 1-Methyl-2-phenyl-1Himidazole-4-carboxaldehyde (9a). A rapidly stirred mixture of 0.7 g (0.04 mol) of 4 and 5.0 g (0.04 mol) of MnO_2 (Aldrich Chemical Co.) in 30 mL of dry tetrahydrofuran was heated under reflux for 1.5 h and subsequently allowed to stir overnight at 23 °C. The solid was filtered and washed with 75 mL of tetrahydrofuran. The filtrate was evaporated in vacuo and the residue crystallized to give 0.5 g (71%) of 9a.

General Procedure for Alkylation of 2-Aryl-1Himidazole-4-carboxaldehydes (8 and 10, Table II). 1-Methyl-2-phenyl-1H-imidazole-4-carboxaldehyde (9a) and 1-Methyl-2-phenyl-1*H*-imidazole-5-carboxaldehyde (9b). Method A. To a stirred solution of 15.3 g (0.089 mol) of 8 and 5.3 g (0.098 mol) of sodium methoxide in 150 mL of anhydrous N,N-dimethylformamide was added 13.9 g (0.098 mol) of iodomethane dropwise at 23 °C over a period of 15 min and the solution allowed to stir for 6 h. After the solution was evaporated under reduced pressure, the residue was taken up in cold water and extracted twice with 150 mL of ethyl acetate. The combined extracts were dried over Na_2SO_4 , concentrated, and filtered to give 8.7 g of a solid which was a mixture of both isomers (9a and 9b), mp 95-101 °C. Passing the filtrate through silica gel gave 3.1 g (total yield: 71%) of additional products (9a and 9b), mp 95-102 °C

Method B. A solution of 100 mL of 30% aqueous potassium hydroxide was added to a vigorously stirred suspension of 5.2 g (0.03 mol) of 8 in 100 mL of dichloromethane, followed by dimethyl sulfate (4.1 g, 0.036 mol) and 0.5 g of Adogen 464 (Aldrich Chemical Co.). After 2 h at 23 °C, the two phases were separated, and the aqueous phase was extracted with 100 mL of dichloromethane. The combined extracts were dried (Na₂SO₄) and evaporated to give 4.1 g of a residue which solidified on standing. The TLC (chloroform-methanol-NH₃, 90:10:1) showed two spots, R_f 0.5 and 0.6, corresponding to two isomers 9a and 9b, respectively.

Separation and Characterization of Isomers 9a and 9b. A solution of 4.6 g of the above mixture of 9a and 9b in diethyl ether was passed through 100 g of silica gel and the column was eluted with ether-hexane (1:1). Crystallization of the combined evaporated residue from diisopropyl ether gave 0.6 g of the pure regioisomer 1-methyl-2-phenyl-1*H*-imidazole-5-carboxaldehyde (9b). The column was further eluted with ether-ethyl acetate (1:1) and the residue from the evaporated fractions was crystallized to give 1.1 g of pure 1-methyl-2-phenyl-1*H*-imidazole-4-carboxaldehyde (9a). This product was identical in all respects with the product obtained by oxidation of 4.

 α -(1-Methyl-2-phenyl-1*H*-imidazol-4-yl)-4-morpholineacetonitrile (13a) and α -(1-Methyl-2-phenyl-1*H*-imidazol-5-yl)-4-morpholineacetonitrile (13b). A solution of 12.1 g (0.186 mol) of potassium cyanide in 12 mL of water was added to a stirred warm (40 °C) solution of 33.7 g (0.181 mol) of a mixture 9a and 9b, 34.5 g (0.181 mol) of p-toluenesulfonic acid monohydrate, and 31.2 g (0.362 mol) of morpholine in 200 mL of dry dioxane and the resulting mixture was heated under reflux for 1.5 h. After cooling to room temperature, the mixture was poured into 500 mL of 10% aqueous potassium carbonate solution and extracted twice with 500 mL of dichloromethane. The combined extracts were washed successively with saturated aqueous sodium bisulfite solution and water, dried (Na_2SO_4) , and evaporated. The cakelike residue was crystallized from ether, giving 42.2 g (83%) of a mixture of 13a and 13b, mp 118–120 °C; ¹H NMR (CDCl₃) δ 2.62 [m, 4 H, N(CH₂)₂], 3.70 [m, 9 H, O(CH₃)₂ and NCH₃], 4.74 (s, CHCN), 4.80 (s, CHCN), 7.10-7.65 (m, 6 H, 5 H, aromatic and H-4 and H-5); mass spectrum, m/e 282. Anal. (C₁₆H₁₈N₄O) C, H. N.

By following the procedure described above, two additional acetonitrile derivatives were obtained: α -[2-(3,4-dimethoxyphenyl)-1-methyl-1*H*-imidazolyl-4-yl]-4-morpholineacetonitrile (14a) [mp 111-112 °C; UV (CH₃OH) λ_{max} 261 nm (ϵ 14750); ¹H NMR (CDCl₃) δ 4.78 (s, 1 H, CHCN), mass spectrum, m/e 342. Anal. (C₁₈H₂₂N₄O₃), C, H, N] and α -[2-phenyl-1-(phenylmethyl)-1*H*-imidazol-4-yl]-4-morpholineacetonitrile (15a) [mp 143-144 °C; UV (CH₃OH) δ max 253 nm (ϵ 10410); ¹H NMR (CDCl₃) δ 2.63 (t, J = 4.5 Hz, 4 H, N(CH₂)₂, 3.73 (t, J = 4.5 Hz, 4 H, O(CH₂)₂, 4.78 (s, 1 H, H-5), 5.13 (s, 2 H, NCH₂), 6.90-7.50 (m, 10 H, aromatic); mass spectrum, m/e 358. Anal. (C₂₂H₂₂N₄O) C, H, N].

 $\overline{2}$ -($\overline{1}$ - \overline{M} ethyl-2-phenyl-1H-imidazol-4-yl)-2-(4-morpholinyl)pentanedinitrile (16a) and 2-(1-Methyl-2-

phenyl-1*H*-imidazol-5-yl)-2-(4-morpholinyl) pentanedinitrile (16b). 2-Propenenitrile, 6.0 g (0.113 mol) was added dropwise to a solution of 21.0 g (0.0745 mol) of a mixture of 13a and 13b in 175 mL of dry tetrahydrofuran containing 5 mL of 30% methanolic potassium hydroxide at 23 °C and the mixture was allowed to stir for 2 h. The ¹H NMR spectrum showed the absence of the protons at δ 4.74 and 4.80 (corresponding to the mixture of 13a and 13b) and IR showed two cyano functions at 2220 and 2228 cm⁻¹, indicating the formation of 16a and 16b. Since attempted crystallization failed, the above mixture was used in the next step.

Sircar et al.

Similarly, 2-[2-(3,4-dimethoxyphenyl)-1-methyl-1*H*imidazol-4-yl]-2-(4-morpholinyl)pentanedinitrile (17a) and 2-(4-morpholinyl)-2-[2-phenyl-1-(phenylmethyl)-1*H*imidazol-4-yl]pentanedinitrile (18a) were obtained, starting from 14a and 15a, respectively.

l-Methyl- γ -oxo-2-phenyl-1*H*-imidazole-4-butanenitrile (19a) and 1-Methyl- γ -oxo-2-phenyl-1*H*-imidazole-5-butanenitrile (19b). A solution of the crude mixture of 17.5 g of 16a and 16b was heated with 75 mL of 80% aqueous acetic acid on a steam bath for 2 h and subsequently was evaporated in vacuo. The residue was taken up with cold aqueous potassium bicarbonate solution and extracted twice with 500 mL of dichloromethane. The combined organic extracts were washed, dried (Na₂SO₄), and evaporated to dryness. Crystallization of the residue from 2-propanol gave 6.1 g (68%) of a mixture of 19a and 19b as white crystals, mp 98-100 °C. Anal. (C₁₄H₁₃N₃O) C, H, N.

2-(3,4-Dimethoxypheny])-1-methyl-γ-oxo-1*H*-imidazole-4-butanenitrile (20a) was obtained from 17 in 71% yield: mp 163–164 °C; UV (CH₃OH) λ_{max} 263 nm (ϵ 11950); IR (KBr) 2225 (CN), 1670 (C=O) cm⁻¹; ¹H NMR (CDCl₃) δ 2.72 (t, *J* = 6.5 Hz, 2 H, CH₂CN), 3.45 (t, *J* = 6.5 Hz, 2 H, CH₂C=O), 3.78 (s, 3 H, NCH₃), 3.94 [s, 6 H, (OCH₃)₂], 6.87–7.35 (m, 3 H, aromatic), 7.65 (s, 1 H, H-5); mass spectrum, *m/e* 229. Anal. (C₁₆H₁₇N₃O₃) C, H. N.

γ-Oxo-2-phenyl-1-(phenylmethyl)-1*H*-imidazole-4-butanenitrile (21a) was similarly obtained, mp 89–90 °C; UV (CH₃OH) λ_{max} 260 nm (ε 8200); IR (KBr) 2241 (CN), 1671 (C=O) cm⁻¹; ¹H NMR (CDCl₃) δ 2.67 (t, *J* = 7.0 Hz, 2 H, CH₂CN), 3.40 (t, *J* = 7.0 Hz, 2 H, CH₂CO), 5.15 (s, 2 H, NCH₂), 6.90–7.50 (m, 10 H, aromatic), 7.5, (s, 1 H, H-5); mass spectrum, *m/e* 315. Anal. (C₂₀H₁₇N₃O) C, H, N.

1-Methyl-γ-oxo-2-phenyl-1*H*-imidazole-4-butanoic Acid (22a). A crude mixture of 17.5 g of the dinitriles 16a and 16b was heated with 40 mL of 20% hydrochloric acid at 100 °C for 6 h. After the solution was evaporated in vacuo, the residue was taken up in cold 20% sodium hydroxide to pH 10.0, and the nonacidic materials were extracted with ethyl acetate, and discarded. The alkaline solution was treated with glacial acetic acid at 0 °C to pH 5.5, causing partial precipitation of the solid. Recrystallization of the latter from ethyl acetate gave analytically pure 22a, mp 191-192 °C; UV (CH₃OH) λ_{max} 275 nm (ϵ 20000); IR (KBr) 1705 (CO₂H), 1668 (Ar C=O) cm⁻¹; ¹H NMR Me₂SO-d₆) δ 2.55 (t, J = 6.0 Hz, 2 H, CH_2 CO₂H), 3.10 (t, J = 6.0 Hz, 2 H, Ar COCH₂), 3.80 (s, 3 H, NCH₃), 7.35-7.80 (m, 5 H, aromatic), 8.20 (s, 1 H, H-5), 12.00 (br, 1 H, CO₂H); mass spectrum, m/e258. Anal. (C₁₄H₁₄N₂O₃), C, H, N.

The mother liquor and aqueous solution contained mixture of both isomers (22a and 22b).

2-(3,4-Dimethoxyphenyl)-1-methyl- γ -oxo-1H-irnidazole-4-butanoic Acid (23a). A solution of 2.1 g (0.007 mol) of 20a in 40 mL of 20% hydrochloric acid and 25 mL of 1-propanol was heated under reflux for 5 h and subsequently evaporated to dryness in vacuo. The residue was taken up in cold water, adjusted to pH 6.5 with NaHCO₃, and filtered to give 1.8 g of crude 23a, mp 196–198 °C dec. Recrystallization from ethyl acetate gave pure 23a as white crystals, mp 200–201 °C dec; UV (CH₃OH) λ_{max} 246 nm (ϵ 12000), 294 (18330); IR (KBr) 1712 (CO₂H), 1665 (Ar C=O) cm⁻¹; ¹H NMR (Me₂SO-d₆) δ 262 (t, J = 6.5 Hz, 2 H, CH₂CO₂H), 3.10 (t, J = 6.5 Hz, 2 H, Ar COCH₂), 3.82 (s, 9 H, (CH₃)₃), 6.85–7.18 (m, 3 H, aromatic), 7.82 (s, 1 H, H-5), 11.90 (br s, CO₂H). Anal. (C₁₆H₁₈N₂O₅) C, H, N.

4,5-Dihydro-6-(1-methyl-2-phenyl-1*H*-imidazol-4-yl)-3-(2*H*)-pyridazinone (25a) and 4,5-Dihydro-6-(1-methyl-2phenyl-1*H*-imidazol-5-yl)-3(2*H*)-pyridazinone (25b; Table

⁽⁷⁾ Dou, H. J. M.; Metzger, J. Bull. Soc. Chim. Fr. 1976, 1861.

⁽⁸⁾ Thompson, W. J.; Terasaki, W. L.; Epstein, P. N.; Strada, S. J. Adv. Cyclic Nucleotide Res. 1979, 10, 69.

Cardiotonic Agents

III). A crude mixture of 13.0 g (0.05 mol) of 22a and 22b in 150 mL of ethanol and 25 mL of glacial acetic acid was treated with 12 mL (0.22 mol) of 85% hydrazine hydrate at 85 °C for 6 h and then allowed to stand overnight at room temperature. The solid was collected and washed successively with water, cold ethanol, and ether, giving 4.2 g of 25a. The filtrate was made slightly basic (pH 8.0) with ammonium hydroxide and extracted three times with 150 mL of ethyl acetate. The combined extracts were washed with saturated aqueous sodium chloride, dried (Na₂SO₄), and concentrated, giving 2.7 g of 25b.

4,5-Dihydro-6-[2-phenyl-1-(phenylmethyl)-1*H*-imidazol-4-yl]-3(2*H*)-pyridazinone (27a). A solution of 3.1 g (0.01 mol) of 21a in a mixture of 20 mL of 1-propanol and 30 mL of 20% aqueous HCl was refluxed for 4 h to give γ -oxo-2-phenyl-1-(phenylmethyl)-1*H*-imidazole-4-butanoic acid (24a). After the solution was concentrated to a volume of 15 mL, 3 mL (0.051 mol) of 85% hydrazine hydrate was added and the mixture was refluxed for 3 h. The reaction mixture was cooled and filtered to give 2.2 g of crude 27a, which was recrystallized to give 1.7 g of analytically pure 27a.

General Procedure for the Preparation of 3(2H)-Pyridazinones from the Corresponding 4,5-Dihydro-3-(2H)-pyridazinones (Table IV). 6-(1-Methyl-2-phenyl-1Himidazol-4-yl)-3(2H)-pyridazinone (28a). A vigorously stirred mixture of 2.2 g (0.0085 mol) of 25a and 12 g (0.142 mol) of MnO₂ (Aldrich Chemical Co.) in dioxane (175 mL) was heated at 70 °C for 22 h. Additional quantity of MnO₂ (8g) was added and heating continued for an additional 5 h. The mixture was filtered and washed with hot dioxane and finally with warm tetrahydrofuran. The combined filtrate and washings were concentrated to yield 0.9 g of 28a as off-white crystals.

Pharmacological Methods. Anesthetized Dog Model. Adult mongrel dogs of either sex were anesthetized with pentobarbital, 35 mg/kg, iv, and were subsequently maintained under anesthesia with a continuous infusion of pentobarbital, 5 mg $\rm kg^{-1}$ h^{-1} . A cannula was inserted into the femoral vein for administering test agents. A Millar catheter tip pressure transducer was inserted into the ascending aorta via the femoral artery for measuring aortic blood pressure. Another similar transducer was passed into the left ventricle via the left carotid artery for measuring left ventricular blood pressure. Needle electrodes were placed subcutaneously for recording a Lead II electrocardiogram (ECG). Heart rate, using a biotachometer triggered from the R wave of the ECG, and the first derivative of left ventricular blood pressure (dP/dt), obtained with a differentiator amplifier coupled to the corresponding pressure amplifier, were also recorded. A period of 30 min was utilized to obtain control data prior to administration of test agent. Depending on solubility of the agent, compounds were dissolved in 0.9% saline solution or in dilute HCl or NaOH (0.1 or 1.0 N) and were diluted to volume with normal saline. Each dose of the test agent was administrated in a volume of 0.1 ml/kg over a period of 1 min in a cumulative manner. Usually, half-log intervals were maintained between doses with typical dosing consisting of four to six doses (for example, 0.01, 0.03, 0.1, 0.3, 1.0 mg/kg) in order to establish any dose-response relationships. A 10-30-min interval was used between doses for the variables to reach a steady state. Only one compound was administered to any one animal. The inotropic activity of a compound was

determined by measuring changes in dP/dt_{max} of left ventricular pressure from preceding base line. Data for only one compound is expressed as means \pm SEM. All others are arithmatic means of two experiments. Statistical analysis of the data was performed with use of a Student's t test for paired or unpaired data. The probability value p < 0.05 was accepted as level of significance.

Isolation of Phosphodiesterases and Assay of Activity. The isolation of different forms of cardiac phosphodiesterase and their characterization was done by following the procedure of Thompson.⁸ The three molecular forms of PDE (type I, type II, and type III) present in guinea pig left ventricular tissue were discretely eluted from a DEAE column using a sodium acetate gradient. Cross contamination was eliminated by chromatography of pooled fractions of each peak. Following complete separation, the combined phosphodiesterase fractions were concentrated to 14% of the original volume, diluted to 65% with ethylene glycol monoethyl ether, and stored at -20 °C (no significant change in hydrolytic activity was observed with storage of up to 6 weeks).

In evaluating the inhibiting effect of the different agents examined on type I, type II, and type III cardiac phosphodiesterases, the enzyme concentration in the assay was adjusted to ensure that reaction velocity was linear for 30 min at 30 °C, and that hydrolysis of substrate ([³H]cyclic AMP or [³H]cyclic GMP) did not exceed 10-20% of the available substrate in the absence of any inhibitor. The concentration of substrate was 1.0 μ M for these studies. All agents examined were dissolved in dimethyl sulfoxide (Me_2SO). The final concentration of Me₂SO in the reactions medium was 2.5%. This concentration of Me_2SO inhibited enzyme activity by approximately 10%. IC_{50} values (the concentration that produces 50% inhibition of substrate hydrolysis) were determined from concentration–response curves that ranged from 10^{-7} to 10^{-4} M for the more potent inhibitors and from 10⁻⁵ to 10⁻³ M for the less potent inhibitors (half-log increments). Two to four such concentration-response curves were generated for each agent, typically using different enzyme preparations for each concentration-response curve.

Acknowledgment. We thank Dr. F. A. MacKellar and his associates for spectral determinations and microanalyses. We are indebted to R. Potoczak and his associates for biological testing. We also thank Dr. W. Moos (Chemistry Department, Warner-Lambert) and F. Parker (Chemistry Department, University of Michigan) for carrying out the NOE experiments. We acknowledge D. Kobylarz for performing the phosphodiesterase studies.

Registry No. 3, 43002-54-6; 4, 99280-78-1; 5, 53292-69-6; 6, 99280-79-2; 7, 99280-80-5; 8, 68282-47-3; 9a, 94938-02-0; 9b, 94938-03-1; 10a, 99280-82-7; 11a, 99280-83-8; 11b, 99280-84-9; 12a, 99280-85-0; 13a, 94938-04-2; 13b, 94938-05-3; 14a, 99280-86-1; 15a, 99280-87-2; 16a, 99280-88-3; 16b, 99280-89-4; 17a, 99280-90-7; 18a, 99280-91-8; 19a, 94938-06-4; 19b, 94938-07-5; 20a, 99280-90-7; 18a, 99280-93-0; 22a, 94938-08-6; 22b, 95402-88-3; 23a, 99280-94-1; 24a, 99280-96-3; 25a, 94938-09-7; 25b, 94937-82-3; 26a, 99280-95-2; 27a, 99280-97-4; 28a, 94937-83-4; 28b, 94937-84-5; 29a, 99280-95-2; 27a, 99280-99-6; 2-propenenitrile, 107-13-1; 3,4-dimethoxybenzonitrile, 2024-83-1; methyl 3,4-dimethoxybenzenecarboximidate hydrochloride, 99280-81-6; 1,3-dihydroxyacetone, 96-26-4.